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 About the Development of this Guide
One of the more difficult tasks in developing a research study is to write a consent form that
describes all the information about the study in such a way that the participants can understand it
and make an informed choice about whether to volunteer to participate in the study.  For years,
CDC investigators have been asking for guidance in writing consent forms and oral scripts.  
In 1997, I asked Mr. Russ Havlak, one of the Institutional Review Board (IRB) chairs,  to
develop a document for investigators to use in writing consents.  Unselfishly, Russ gave his time
to produce the guide while continuing his regular job responsibilities.  After much thought about
the best approach and what would be most useful to investigators, Russ embarked upon a long,
tedious process of reviewing CDC IRB approved consent forms.   He then wrote a document that
explains the information, element by element, that should be contained in a consent form and
used examples from existing approved consents as illustrations.  The document he produced is,
perhaps, one of the best documents available on writing consent documents and oral scripts.
We are greatly indebted to Russ for developing this reference guide for investigators.  Russ
began serving on a CDC IRB in 1980 and became a chair in 1994.  During that time, he has been
deeply committed to the ethical principle that potential participants should freely chose whether
to participate in research.  That voluntary choice can only be made when investigators use a
consent process that fully informs participants about the research in a way that participants can
understand the information.  Russ has spent countless hours reading and editing consent forms
for all of us, in each case trying to make the consent more understandable, informative and non-
coercive.  This document reflects his vast knowledge and great skill in writing consent forms.  
Thank you, Russ.
Marjorie A. Speers, Ph.D.
Deputy Associate Director for Science
     
Foreword
The Centers for Disease Control and Prevention (CDC) has had an Institutional Review Board
(IRB) for almost 30 years.  The IRB’s role is to review proposed studies and approve those which
comply with 45 Code of Federal Regulations, Part 46 (45 CFR Part 46), the federal regulations
that govern research involving human participants.  However, the guiding vision of the IRB has
less to do with review and approval than with the idea of helping all of CDC to carry out ethical
research.
The CDC IRBs have reviewed a couple of thousand study protocols over the years, giving them
insight into the strengths of CDC research and weaknesses common to the process.  Top among
the problem areas are consent documents—both written forms and oral consent scripts.  Consent
in human participant research should be a process that continues from the time participants sign
up for a study to the time they complete the study or withdraw from it.  The consent form or oral
consent script is but one piece of that process, but a piece which the IRB is obligated to take very
seriously.
 
This is a reference to help CDC investigators write research consent forms and scripts that
conform to the Federal Regulations.  It draws on the wisdom gained by the IRB and offers
suggested wording similar to that found in CDC consent forms the IRB has approved.  No
attributions are cited, but this does not lessen the appreciation to the many CDC investigators
who contributed to this reference.
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Introduction
The research we conduct at the Centers for Disease Control and Prevention (CDC) provides
information that is vital to our mission.  An integral part of this research is obtaining informed
consent of all participants, as required by 45 CFR 46, the federal regulations that govern research
involving human participants.  Throughout this reference, 45 CFR 46 is referred to as “the
federal regulations.”
  
This reference will provide:
C A general overview of the principles and requirements of informed consent
C Tips on writing and formatting consent forms that are easy to read and understand
C A section-by-section guide for crafting an effective consent form 
We recognize that consent can be obtained using oral consent scripts, as well as consent forms. 
We have chosen to focus on consent forms because they are the format required by the Federal
Regulations and the most common form of consent in CDC studies.  Most of the guidance
provided in this reference will apply both to consent forms and to oral consent scripts.  However,
we will discuss the differences between the two when they arise.
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 Principles and Requirements of Informed Consent
Research involving human participants is explained in the federal regulations.  The combination
of two definitions there defines research involving human participants to be a systematic
investigation, including research development, testing and evaluation, designed to develop or
contribute to generalizable knowledge, and which involves a living individual about whom an
investigator conducting research obtains (1) data through interventions or interactions with the
individual or (2) identifiable private information.  Perhaps the most basic ethical requirement of
this kind of research is informed consent.
Basic Principles of Informed Consent
The federal regulations set out four overriding principles which are meant to apply to all
consents, unless there are specific exceptions made or allowed elsewhere in the regulations. 
These principles are:
1. Human research can proceed only with informed consent unless waived under the Federal
Regulations - No investigator may involve a human being as a participant in research covered
by the federal regulations without legally effective informed consent of the participant or
his/her legally authorized representative.
2. Minimize coercion in obtaining consent - An investigator shall seek consent under conditions
that provide the prospective participant or his/her representative sufficient opportunity to
consider whether to participate, and that minimize the possibility of coercion or undue
influence.
3. Consent must involve understandable language - The information that is given to the
prospective participant or his/her representative shall be in language the participant or the
representative can understand.
4. Waiver of rights is prohibited in the consent process - No informed consent, whether oral or
written, may include any exculpatory language through which the prospective participant or
his/her representative is made to waive or appear to waive any of the prospective participant’s
legal rights, or made to release or appear to release the investigator, the sponsor, the
institution, or its agents from liability for negligence.
1 Minimal risk means that the probability and magnitude of harm or discomfort
anticipated in the research are not greater in and of themselves than those ordinarily
encountered in daily life or during the performance of routine physical or
psychological examinations or tests.  Both factors must be considered in weighing
whether a risk is greater than “minimal risk.”  In deciding if research involves
minimal risk, the IRB is expected to consider risk from study procedures in relation to
all persons eligible to participate--not just from the perspective of a person in good
health or of someone with health problems matching circumstances of the research.
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Required Elements of Informed Consent
The federal regulations list eight required elements of informed consent.  These are:
1. Purpose and Procedures - You must tell a prospective participant that the study involves
research, explain the purpose of the study and the length of time you expect the person to
participate, describe the procedures to be followed, and identify any experimental procedures.
2. Risks - You must describe any reasonably foreseeable risks or discomforts to the prospective
participant.
3. Benefits - You must describe any benefits to the prospective participant or to others which
may reasonably be expected from the research.
4. Alternatives - You must disclose any appropriate alternative procedures or courses of
treatment that might benefit the prospective participant.
5. Confidentiality - You must tell prospective participants whether their records will be kept
confidential and, if so, explain the level of confidentiality.
6. When There is Greater than Minimal Risk1 - You must tell prospective participants whether
they will receive any compensation and/or medical treatments if injury occurs and, if so, what
compensation or treatment will consist of, or where to obtain further information.
7. Persons to Contact - You must tell prospective participants whom to contact if they have
questions about the research and their rights as a study participant, and whom to contact if
they have an injury that may be related to the research.
8. Voluntary Participation, Refusal, and Withdrawal - You must state that participation is
voluntary, that refusal to participate involves no penalty or loss of benefits to which the
person is otherwise entitled, and that the person may discontinue participation at any time
without penalty.
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Additional Elements of Consent
When appropriate, the following six additional elements of consent should be included:
1. Unforeseeable Risk - You should state that the study treatment or procedures may have risks
for the prospective participant (or to the embryo or fetus, if the participant is or may become
pregnant) that you cannot currently foresee.
2. Termination of Participation Without Consent - You should explain anticipated
circumstances under which the investigator may terminate the participant’s further
involvement without regard to the person’s consent.
3. Additional Costs - You should describe any additional costs to prospective participants that
may result from participation in the study.
4. Consequences and Process of Withdrawal - You should explain how participants can leave
the study and what may happen if they choose to withdraw. 
5. Impact of Significant New Findings - You should state that participants will be told of any
significant new findings developed during the research which may relate to their willingness
to continue in the study.
6. Number of Participants - You should tell prospective participants the approximate number of
persons involved in the study.
Alteration or Waiver of Consent
In some cases, the federal regulations allow an IRB to approve a consent procedure which
excludes or alters some of the 14 required and situational elements discussed previously or calls
for a waiver of consent entirely.  These situations fall into two categories. 
1. Research Involving Public Service or Benefit Programs
a. The research or demonstration project is to be conducted by or subject to the approval of
state or local government officials and is designed to study, evaluate, or otherwise
examine:
(1)  Public benefit or service programs;
(2)  Procedures for obtaining benefits or services under those programs;
(3)  Possible changes in or alternatives to those programs or procedures; or
(4) Possible changes in methods or levels of payment for benefits or services under those
programs, AND  
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b.  The research could not practicably be carried out without the waiver or alteration.
2.  Other Research (not involving public service or benefit programs)
To approve an alteration or waiver of consent for research involving other than public benefit
or service programs, an IRB must find and document the following:
a. Minimal risk - The research involves no more than minimal risk to the participants;
b. No adverse affects - The waiver or alteration will not adversely affect the rights and
welfare of the participants;
c. Research not practicable otherwise - The research could not practicably be carried out
without the waiver or alteration; and
d. Follow-up information available - Whenever appropriate, the participants will be given
additional pertinent information after their role in the study is over.
Waiver of the Need for Signed Informed Consent
As a rule, consent forms and oral consent statements must be signed to be legally valid. 
However, the federal regulations recognize that, in some situations, having a signature on record
is not in the best interest of the participant.  The regulations state that an IRB may waive the
requirement for a signed consent form for some or all of the prospective participants in a study if
one of the following applies:
1. Consent is the only link - The only record linking the participant to the research would be the
consent document, and the principal risk would be potential harm resulting from a breach of
confidentiality.  Prospective participants must decide if they want documentation linking
them with the research and their wish is to govern; or
2. Minimal risk and a common nonconsent procedure are involved - The research presents no
more than minimal risk of harm to participants and involves no procedures for which written
consent is normally required outside of the research context.
When the requirement for signed consent is waived, the IRB may require the investigator to
provide prospective participants with a written statement about the research. 
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How to Make Consent Forms Easy to Read 
and Understand
Only if participants understand what you’re telling them about the study and their participation
can they give “true informed consent.”  The tips that follow will help you write consent forms
that are easy for prospective participants to read and understand. 
Write at a level that matches the reading ability of your prospective
participants.
We tend to assume that if our colleagues can understand what we’ve written, others can too. 
This assumption too often proves false.  Most CDC studies target persons from economically and
educationally disadvantaged populations whose reading skills tend to be at or below the 8th grade
level.  However, most consent forms for these studies are written at or above the 12th grade
reading level.  
To increase the likelihood that your consent form will be understood, you should:
C decide at which reading level to write your consent form
C follow the rules for writing easy-to-read materials
C test the reading level of your consent form and, if too high, make any changes needed to
lower the reading level
This section will help you complete these steps.
A. At which reading level should you write your consent form?  
The National Adult Literacy Survey (NALS), conducted in 1993, found that nearly half of all
American adults read at very basic levels.  This percentage was much higher among welfare
recipients, older adults, racial and ethnic minorities, and disadvantaged and inner-city
populations.  In addition:
h Only 21% of responders performed in the highest levels.
h Most people at the lowest levels did not perceive their problem; they described themselves as
being able to read “well” or “very well.”
h Adults with relatively few years of education were most likely to perform in the lower levels
than those who completed high school or received some postsecondary education.
h Older adults were more likely than middle-aged or younger adults to demonstrate limited
literacy skills.
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The NALS is the source of the estimate that the “average” American reads at or below the 8th 
grade reading level.  Also, the NALS found that a significant proportion of persons from
disadvantaged, inner city, racial/ethnic minority populations read even below that level.  In
addition, the NALS found that perhaps for reasons of either self-deception or embarrassment,
those with profound reading difficulties are unlikely to admit it.  Thus, an investigator cannot
necessarily rely on a prospective participant’s reaction to a consent form as signifying the
achievement of “true informed consent.”  It argues for making any form as readable (hence,
understandable) as possible, but always making it the centerpiece of a consent “process”
involving enough dialogue to ensure that the person truly understood the words in the consent
document.
B. What tools are available to grade the readability of a consent form?
 Several tools are available to help a CDC investigator determine if a consent form will be
readable by a study population.  One is an electronic readability formula through Grammatik in
WordPerfect versions 6.1 and above.  First, if the consent form is part of the protocol, rather than
in a separate document, copy the consent to a new blank document.  Go into Tools and select
Grammatik.  From the dialogue box, select View, and under that, Statistics.  Then select
Readability, which is presented using the Flesch-Kincaid Readability Test.  In WordPerfect 7.0,
this is found under Analysis.  The resulting grade is based on the number of words per sentence
and the average number of syllables per word.  For persons (such as IRB members) who often do
not have electronic versions of consents to test using Grammatik, two convenient manual options
are available:
1. SMOG - which bases grade level on a scale that counts the number of $3 syllable (or
polysyllabic) words in 30 sentences, 10 each from the beginning, the middle, and the end of
the document.  Readability of a piece with less than 30 sentences is judged on the scale by
taking the average number of polysyllabic words from the sentences and multiplying that
average by 30.  SMOG is quick and easy to use.  It equates well with other formulas at the
high end of the readability scale.  It only drops to the 5th grade level, and really does less well
when measuring a document written #8th grade level.  It tends to overrate readability level at
these lower levels.  The SMOG scale appears in Appendix A, along with references to
formulas for testing the readability of materials written in Spanish.
2. Fry Graph Reading Level Index - which bases the grade level on a two-way graph with
average sentences/100 words on one axis and average number of syllables/100 words on the
other.  Derive the averages by counting 100 words (including proper nouns,
initials/acronyms, and number sets) at the front, middle, and end of the document.  Then
calculate the means of the three sentence and syllable counts.  The Fry Graph Reading Level
Index involves more work than SMOG, but gets easier with practice.  It is probably more
sensitive than SMOG at all reading levels, but is much more sensitive on the lower end of the
readability scale.  A copy of the Fry Graph, with more tips on its use, also appears in
Appendix A.  Jane Root, Ph.D., reading expert and Fry Graph advocate has a rule to only
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Tips for eliminating polysyllabic words
1. Find a syno nym.  For ex ample, rep lace “com pensate” w ith
“pay” or “re pay.”
2. Use active  voice.  Yo u can chang e “It is recomm ended”  to
“We re comme nd.”
3. Try a combination of less complex words.  Instead of
“researche rs,” try “peop le doing the stu dy.”
4. Start over.  If replacing words and finding synonyms is too
much trouble, try rewriting the sentence.  You may find an
easier way to sa y what you nee d to say.
5. Ask if the term can be deleted.  In some cases, you may even
be able to delete a whole sentence, if the information is not
essential to inform ed conse nt.
6. Live with it.  Accept that some terms just can’t be fixed.  For
example , you can’t repla ce or dele te terms like “ba ndages,”
“reaction,” “p ositive,” and  “negative.”  H owever, re latively
few polysyllabic  words will fall into this c ategory.
count once a medical/technical term with which there can be no doubt that the reader is
already familiar, e.g., “diabetes” in a study consent for diabetics.  The CDC IRB has also
adopted this rule.
C. How do you write (or rewrite) a consent so that it achieves an #8th grade
reading level?
You can get to a #8th grade reading level, and maximize comprehension in your consent forms by
following some rules described below, combined with some creative writing and use Appendix
B, a job aid that cites alternatives to complex terms that the IRB has found common to CDC
consent forms. 
Rule 1 Assume that your study participants will not recognize any $3 syllable words you use.
Rule 2 Accept that some $3
syllable words (e.g., proper
nouns such as organizations,
places, diseases/organisms,
and persons’ names) may be
abbreviated (e.g., CDC, in




[Blood Center]) or reduced
in their number of usages;
but most cannot be replaced
or deleted entirely, so use the
minimum you need to and
move on.
Rule 3 Assume that nearly every
other $3 syllable word, other
than proper nouns, CAN be
replaced, and that doing so
will improve readability
(since at the 12th grade
reading level the ratio of
these “replaceable” words to $3 syllable proper nouns is about 8 to 1) in the usual CDC
consent form.  For example, the following actual wording in a CDC consent:  “Your
name and other information which could be used to identify you will be kept as
confidential as legally possible, ” upon revision was replaced with:  “Your name and
what you say to us for this study will be kept private to the extent allowed by law.”  The
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5 replaced $3 syllable words proved expendable as the sentence, now more readable,
sends the same basic message.
Rule 5 Be less concerned with the length of the consent than its ability to be read and
understood.  Replacing single complex terms with a series of less complex ones often
will lengthen what might otherwise have been a short consent.  Balance is important. 
Brevity is desired in that it encourages one to read a document that they might not if it
was longer.  However, the esthetics of achieving that brevity is sometimes purchased at
the cost of informed consent.
Rule 6 In addition to minimizing the number of $3 syllable words in a consent form, its
readability and comprehension can be improved by:
a. Using the active voice - Concentrating on using the active voice can prevent
readability problems from the outset;
b. Limiting use of medical/technical terms - At times their use is unavoidable, but
repetition can be limited by using abbreviations and some creative alternatives.
c. Keeping your sentences short - Short sentences are more readable than long ones. 
Whenever possible, break up sentences over 20 words; and
d. Limiting ideas to one per sentence - Persons with weak reading skills will have more
trouble understanding complex sentences than ones which transmit only a single
idea.  If you need to keep two ideas closely connected, consider using a semicolon to
break them apart in a single longer sentence.
Write to prospective participants--don’t put words in their mouths.
We’ve all seen (and probably written) consent forms written in the first person singular, the “I”
construct.  These consent forms result in sentences that start out like this:  “I understand that I
will be asked...,” “I realize that I will be given...,” and “I recognize that I may be at some risk
for...”  These sentences almost always contain words with three or more syllables and tend to be
hard to read.  This sentence structure also seems to place the onus on the participants to
understand rather than on the investigators to explain.  
Writing to your prospective participants—rather than putting words in their mouths—sounds
much more natural and results in language that is easier to read and understand.  The sentences in
the previous paragraph, for example, are much easier to understand when written as follows: 
“We will ask you...,” “We will give you...,” and “You may be at risk for...”  These sentences
mimic natural conversation and may more readily facilitate conversation between participants
and investigators, a critical step in the consent process.
You should avoid first person singular construction for other important reasons.  It is a legalistic
form and, therefore, can be intimidating to prospective participants.  For this reason, IRB experts
and the Office for Protection from Research Risks (OPRR) view this construction as coercive,
which is not allowed under the federal regulations.
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Organize your consent form in sections.
The format of a consent form, as much as its content and phrasing, influences how well 
prospective participants understand it.  The best way to organize your consent form, according to
the IRB, is to use headings to separate subject matter.  In addition to increasing comprehension,
this format can lessen the risk of omissions and redundancies.
Below is one suggested format, which allows you to cover all of the required and situational
elements of informed consent.
< Introduction
< Purpose of the Research
< Procedures




< Compensation (if appropriate)
< Right to Refuse or Withdraw
< Storage of Specimens for Future Testing (if appropriate)
< Alternative Treatment (if appropriate)
< Persons to Contact
< Your Consent(s)
< Signature Lines, Approval Boxes, Witness Signature Lines, and Designations
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Three Problem Elements to Avoid
Before using your consent form, edit it carefully.  Or, better yet, have someone else
edit it for you.  A thorough review can help you avoid three problem elements.
1.  Proselytizing words and phrases
It’s tempting to try to “sell” your study to prospective participants by focusing
on how great the benefits can be both to the individuals in the study and to
society at large.  But a consent form must present all information, good and
bad, if true informed consent is to be obtained.  Reread your consent form to
make sure that it does not understate the risks or overstate the benefits. 
You may want someone who is not involved in the study to read your
consent form to make sure it presents an honest and objective picture of the
study. 
2.  Adverbs and Adjectives
Minimize the use of adverbs and adjectives in consent forms.  These
modifiers can result in unintended influence on prospective participants. 
One might be more willing to participate in a study with risks involved if it will
lead to “vital” information about a disease or “substantially” improve
understanding of a health issue.
3.  Spelling Errors
Errors reflect poorly on the author of a document of any type.  Do not rely on
your word processor’s spell check.  You still need to reread your consent
form carefully to eliminate spelling errors.  For example, your word processor
won’t know that “you” is supposed to be “your” or that “them” should be
“then.”  Manually proofread your consent form after having applied an
electronic spell check.  Also, an editor can proofread your consent form
quickly to find errors like these.
Note: The principles and rules discussed in this section also apply to writing an oral
consent script.
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A Section-by-Section Guide to Writing Consent Forms
This guide will walk you through the process of writing a consent form, section-by-section.  It
addresses the common situations you will face in conducting research at CDC, as well as some
less common situations.  Throughout the guide, you will see examples of wording similar to that
which the IRB has approved in CDC consent forms.  These examples appear in “bolded italics in
quotation marks.”
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INTRODUCTION - Common Consent Situations
Each consent form should begin with a clearly labeled
introduction that does the following:
1. Clarify the Research Purpose - You want prospective
participants to know that they are giving their consent to
take part in research and not agreeing to let you perform a
medical procedure, get medical records, or some other
routine purposes.  If the project name you cite in the
Introduction section does not convey this idea, use a
simple declarative sentence.  For example,
“This project we want you join is a research study.”
2. Identify the Study Sponsors - Identify all of the agencies,
organizations, and institutions that are asking the
prospective participant to take part in this research so that
the participant knows who is responsible for what the
participant is being asked to do.  This will likely require
the use of several polysyllabic words—mainly proper
nouns and medical/technical terms.  To improve the
readability of your consent form, you want to give
abbreviations and simplified terms now so participants will
recognize them later in the form.  For example,
“The Tropical Disease Research Centre and the
Centers for Disease Control and Prevention (CDC)
in Atlanta, Georgia, USA, are doing a study on
malaria.”
3. Summarize the Problem - Summarize the (actual or
potential) illness-producing problem which is important
enough to justify both the study and the person’s
participation.  For example,
“Doctors have learned a lot about what affects the
health of mothers and babies.  But there is still
much that we do not know.  Through this study, we
hope to learn more about what causes babies to be
born premature.”
4. Explain the Disease - Most CDC studies involving human





participants are focused on a specific disease, syndrome,
medical condition, or environmental risk.  Prospective
participants, in general, may know something about the
study focus.  However, an investigator cannot assume that
they know enough to give their informed consent.  The
challenge is to provide an explanation in which the words
are readable and the content can be understood.  The
following language, approved by the IRB, is a good
example:
“Hepatitis B is an infection of the liver caused by the
hepatitis B virus (HBV).  Acute hepatitis sometimes
begins with mild feelings of illness.  These may
include loss of wanting to eat, a feeling of illness
coming on, and being very tired.  A person also
could have an upset stomach, vomiting, stomach
pain, dark urine, and jaundice (yellow eyes and
skin).  At times, a skin rash and joint pain can
occur.”
5. Explain Complex Concepts - CDC studies often require
that prospective participants understand rather complex
concepts if they are to give fully informed consent.  Some
of these concepts include multi-drug resistance, disease
diagnosis, and complicated testing procedures.  The
examples below are from CDC IRB-approved consent
forms and do well in explaining complex issues in fairly
simple language.
“TB germs are strong and take powerful drugs to
kill them.  Some TB patients have mutant germs
which are “resistant” to the TB drugs.  This means
that the germs are so strong that they are not killed
by some of the drugs.  TB germs can become
resistant if TB patients do not swallow their pills
every day.  TB patients who do not take the pills can
spread these resistant germs to others.  Those other
people can become sick with resistant TB.  Patients
who have these resistant germs must be treated with
special drugs to be cured.”
*****
“The long-term storage place of lead in the body is
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Answer “Why me?”
in the bones.  We will measure the amount of lead in
your bones and the density of your bones.  This is to
assess the amount of lead in the bones and if that
lead has had any effect on them.  We measure bone
density based on X-rays with low radiation doses. 
We will measure the minerals in the bones in a
person’s hip and spine.  These measures will take us
30-60 minutes of your time.  We will measure the
amount of lead in the bone by using a technique
called X-ray fluorescence.  For this test, we will ask
you to sit still for between 15-30 minutes.”   
6. Answer the Implicit “Why Me?” Question - Explain why
prospective participants have been chosen.  This reason
may differ for study participants and control participants. 
Suggested readable wording akin to that which the IRB has
approved in CDC consent forms include:
“We are asking you to be in this study because you
are a resident of Goodwin House.  We are asking
people who got flu vaccine there during the past 5
years and also some who did not get the vaccine.”
*****
“We are asking you to be in the study because you
live in the farming area which may have exposed





INTRODUCTION - Less Common Situations
The Introduction section almost always addresses common
research situations.  However, two other circumstances
occasionally arise within this section which bear mentioning.
1. CDC’s Participation Should Not be Cited in the Consent -
On rare occasions, usually in studies conducted outside of
the United States, circumstances arise where it is
strategically necessary not to cite the role of CDC as a
sponsor or active participant in the research.  The IRB
understands that such situations can occur.  However, the
process requires the investigator to explain the background
and ramifications in detail as part of justifying any such
deletion of a reference to CDC’s role.
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Blinding
2. Participants Must be Blinded to Some Aspect of the Study
On rare occasions, full knowledge of the study aspects
usually addressed in the Introduction section might
produce either a selection bias among prospective
participants or a response bias among actual participants. 
The IRB understands that certain types of CDC
epidemiologic studies may face this potential problem. 
However, the IRB may alter the consent process if it can
do so according to the criteria in the federal regulations
(see page 7 of this reference).  Therefore, if either the
problem summarization and/or “Why me?” explanation
segments of the Introduction section are points in the form
which require blinding, the informing language should be
inserted in its place. Suggested readable wording akin to
that which the IRB has approved in CDC consent forms
include:
“We do not want to influence your (enrollment/
answers) so there are some details of the study
(about why we asked you to enter the study) that we
cannot tell you about until the study is over.  But at
the end of the study, we will send you a report of our




PURPOSE OF THE RESEARCH - Common Situations
Use the Purpose section to explain the research question to be
answered by the study.  While this information could be
included in the Introduction section, it is helpful to discuss it
separately.
We have not included any specific examples in this section
because each consent form calls for unique phrasing based on
the research question associated with its protocol.  However,
remember that the wording in this section should be easy to
read and understand; do not simply restate the research
protocol







PURPOSE OF THE RESEARCH - Less Common
Situations
The Purpose of the Research section almost always is a
straightforward explanation of the research question.  On rare
occasions, however, the circumstances of the research dictate
otherwise.
 Participants Must be Blinded to Some Aspect of the Study -
As in the Introduction section, on rare occasions, full
knowledge of the study aspects usually addressed in the
Purpose of Research section might produce either a selection
bias among prospective participants or a response bias among
actual participants.  (Procedures for requesting an alteration of
informed consent begin on page 4 of this reference.)  The
wording used here is roughly identical to what is suggested for
the Introduction section on the previous page.
“Because we do not want to influence your
(enrollment/ answers), there are some details of the
purpose of the study that we cannot tell you about
until the study is over.  But at the end of the study,
we will send you a report of our findings and answer





PROCEDURES - Common Situations
Use the Procedures section to explain the study design.  While
this will vary from one study to another, certain procedures
are common to CDC consent forms, and all forms should
include a statement that participation is voluntary.
1. Participation is Entirely Voluntary - Tell prospective
participants early in the consent form that being part of the
study is completely their decision.  This message can be
introduced here, in the Refusal/Withdrawal section, or in
both places.  The last choice results in some redundancy,
but it is advised due to the importance of the message. 
Suggested readable wording akin to that which the IRB
has approved in CDC consent forms include:
“You are free to join the study or not.  If you do not
join, you will not lose any health care service that
you expect to get apart from this study.”




Blood to be Taken and How
2. Randomization - Randomization is common to CDC
research protocols.  If your study design employs
randomization, you must explain it in the consent form. 
Some CDC investigators have devised simplified wording
to explain this procedure.  Suggested readable wording
akin to that which the IRB has approved in CDC consent
forms include:
“The decision of who receives calcium and who
receives starch is random, like the lottery.  Nobody,
neither you nor us, will know who is receiving
which.  This will be kept secret until the end of the
study, when we all will know who received which
supplement.”
*****
“If you agree to be in this study, you will be in one
of the two groups by chance.”
*****
“You have a fifty-fifty (50%) chance of being in one
of two groups.”
3. Blood to be Taken and How - Taking blood is a procedure
common to many CDC studies.  The consent form needs
to explain the amount of blood to be taken, in equivalent
teaspoons, tablespoons, or other measures with which
most participants would be instantly familiar.  Also, the
consent should specify how and from where the blood will
be taken.  Suggested readable wording akin to that which
the IRB has approved in CDC consent forms include:
“If you choose to be in this study, we will draw
about 30 ccs (2 to 2 ½ tablespoons) of blood from
the vein in your arm.”
*****
“If you allow your child to be part of this study, we
will take about 1 cc (about 2 or 3 drops) of blood by
using a finger stick.”




“We will collect the blood in a tube the size of a
man’s finger.  It holds 5 ml, or the same amount as
one teaspoonful.”
4. Taking Other Samples - While taking blood is common in
CDC studies, it is not the only type of specimen which is
needed for research.  Examples of readable working akin
to what the CDC has approved in CDC consent forms for
a number of these situations include:
[Saliva Specimens]
“To collect a saliva sample, we will ask you to hold
a small cotton pad between your cheek and lower
gum for 2 minutes.  This pad will have a salty taste,
but does not present a risk to you.”
[Nasal Specimens]
“We will obtain this sample by placing a cotton-
tipped swab inside your nose.  We will twirl it gently,
and leave it in place for a few minutes before we
remove it.”
[Nasopharyngeal Specimens]
“We will collect the nose sample by very briefly
placing a small cotton swab into your nose.  We will 
quickly wipe a second swab across the back of your
throat.  We will test these samples to see if your
illness was caused by the flu virus.”
[Vaginal Secretion Specimens]
“While you are lying down, you will place a syringe
filled with a mild salt water solution in your vagina,
as you would a tampon or douching syringe.  You
will squeeze out solution, and then draw it back into
the syringe.  Then you will put the solution that is in
the syringe into a test tube.”
[Genital Ulcer Specimens]
“If you are a man or a woman with ulcers or sores
in the genital area (on, in, or near your penis or
vagina) - We will take a sample of fluid after
cleaning the base of the ulcer.  As a rule, this is
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Procedures Not to be Done
PROCEDURES 
Questionnaires/Interviews
painless but it may cause some slight burning.  We
will send this sample out of the country for testing. 
Thus, it will not be available for deciding on the
treatment of your ulcer or sore.” 
5. Procedures Not to be Done - In some cases, it is as
important to cite the procedures which are not involved as
to cite those which are important.  An example of readable
wording addressing such an issue akin to that which the
IRB has approved includes:
“Your doctor or nurse practitioner will take a
sample from your cervix (the opening of your
womb).  They will take two swabs (like a Q-tip) for
this study during your routine scheduled internal
exam.  No internal exams will be performed just for
this study.  We are asking you to be in this study
because you are going to have an internal exam
anyway.”
6. Questionnaires/Interviews - Administering questionnaires
and conducting structured interviews have always been
common components of CDC research.  In your consent
form, find a more readable synonym for the words
questionnaire and interview (e.g., “survey”), if possible. 
Then explain how much time is required, the nature of the
questions (noting any sensitive areas of questioning), and
the fact that the participant is not required to answer any
of them, for any reason.  A common error to avoid is
combining the statement that some questions may be
sensitive with the fact that participants may choose not to
answer any question.  This can seem to put a condition on
declining to answer (e.g., feeling embarrassed, feeling it is
too sensitive, etc.).  You want participants to know that
they can decline to answer any question, for any reason,
without feeling a need to justify their reason.  Suggested
readable wording akin to that which the IRB has approved
in CDC consent forms include:
“We will ask you to take part in a survey in which
we will ask you a number of questions.  This survey
will take about ½ hour.  During this survey, we will
ask you questions about the health care you got
when you were last pregnant and about having HIV. 




Review of Medical Records
PROCEDURES 
Some of these questions ask about your sex life and
may concern you.  You may choose not to answer
any question and for any reason.  Say that you want
to pass on the question and we will just move on to
the next one.”
*****
“...It’s all right to skip any question you don’t want
to answer.  You may end the questions any time you
want.  This won’t affect any care that you or your
child expect to get at the clinic or from your doctor.”
 
7. Time Commitments - It is important to tell prospective
participants how much time their enrollment will entail. 
This can be done procedure by procedure, as above, or in
summary fashion.  Suggested readable wording akin to
that which the IRB has approved in CDC consent forms
include:
“We will need less than 5 minutes to take the blood
sample.  The interview will take about 30 minutes,
and the other tests should be over in 1½ hours.” 
8. Consent for Review of Medical Records - Often the study
design of a CDC protocol will call for a review and
abstraction of a participant’s medical records.  The
Procedures section is where this is explained.  Suggested
readable wording akin to that which the IRB has approved
in CDC consent forms includes:
“We need to check with doctors who have given
your child health care.  They need to confirm that
your shot record shows all of the vaccines s/he has
gotten and that we haven’t missed any.  To let us do
this, we ask you to sign a form to let those doctors
share your records with us.”
9. Storage Without Identifiers - The Procedures section
should be used to announce plans to store leftovers of
blood or other specimens for future testing when the
specimens will be stored WITHOUT identifiers.  (A
separate section is needed when specimens are to be stored
WITH identifiers—see page 44 of this reference
22Consent for CDC Research—A Reference
Note: The last sentence of this example is very important.  You must let
prospective participants know that they do not have to let you store their
blood or other specimens—it’s their choice.






document.)  Meanwhile, suggested readable wording akin
to that which the IRB has approved in CDC consent forms
for announcing the intent to store specimens without
identifiers includes:
“We would like to store any blood that is left over
after we do your test.  We plan to use this sample for
studies we will do in the future.  We will store your
sample with some data about you, such as your age,
race, sex, and about your heath problem.  But we
will not put your name on the sample, and there will
be no way to know it is yours.  Thus, we will not be
able to report back any test results to you.  You can
decline to let us store your blood and still be in this
study.”
PROCEDURES - Less Common Situations
Occasionally, CDC protocols involve the use of mail and
telephone questionnaires, focus groups, placebos, or situations
in which it may be necessary to break the study code.  Because
these situations can be inherently more sensitive than some of
the common situations, you must explain them in words
prospective participants can understand.
1. Mail and Telephone Questionnaires - Interviews and
questionnaires are common procedures in CDC studies,
and sometimes they are administered by mail or over the
phone.  These involve the same elements of informed
consent that apply when such instruments are administered
in person, plus some special elements:  assertive implied
consent (through the return of a questionnaire), a reminder
of the right of refusal to answer questions, and an
explanation of the procedure to account for responses. 
Examples of readable wording akin to that which the IRB
has approved for CDC consents include:
[Assertive Implied Consent]
“We will take your return of the completed survey as
your consent to be part of this study.”
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[Right of Refusal to Answer Questions]
“It would be helpful to have a complete response. 
But, you are free to choose not to respond to any
part of the survey.  We will not contact you further
about any questions which you decline to answer.”
[Explaining Response Accounting]
“You will see that your survey does not ask your
name or for any other way to identify you.  But, you
will see that it is stamped with a number.  That
number matches to your identity on a list.  We will
keep that list only to track who has and has not
responded.  We expect to follow up with those who
have not sent us a response.  After we have
performed our follow-up, we will destroy the list. 
This will break any link to the names of persons
who completed the survey.”
2. Genetic Testing - While genetic testing has not been
common in studies thus far, genetic testing technology and
its potential applications are growing.  The process spans a
wide spectrum of biomedical applications, including
testing the DNA of infecting organisms; identifying the
genetic predisposition of participants and their families to
life-threatening, untreatable, hereditary conditions; and
pinpointing potential cures for diseases and illnesses.  If
your study will involve genetic testing, you must
thoroughly explain it in your consent form.  Examples of
readable wording describing genetic testing akin to that
which the IRB has approved in CDC consents include:
“The only genetic testing we will do on your blood is
to help us learn more about the disease.  It may help
us develop better tests for schistosomiasis.”
*****
“We will test part of this blood sample to study your
child’s DNA and the folic acid and homocysteine
content of his/her blood.  Tests will be done on
samples with names removed.  There will be no way
to link a sample to your child.  This means that for
this study, we cannot give you back any test results.” 
*****
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“We would like to test your blood to learn your
human leukocyte antigen, or HLA type.  Your HLA
type is a basic genetic marker that helps the body
recognize itself.  For instance, HLA markers help
your body detect and fight cells that are infected or
abnormal (such as cells infected with a virus).  And
these markers avoid other healthy cells in the body. 
We will use this to learn if a certain HLA type is
associated with certain immune responses to
measles.”
3. Focus group taping and related issues - The use of focus
groups is becoming much more common.  The procedural
requirements to carry out an effective focus group session
(e.g., to transcribe responses and/or to video/audio tape the
interaction) raise some special concerns.  These include
how participants are identified in the focus group session,
how the session will be observed and recorded, and
confidentiality issues related to any recordings.  These
concerns need to be addressed in the protocol, but should
also be explained in the consent form.  Suggested readable
wording akin to that which the IRB has approved in CDC
consent forms includes:
“For the focus group, we will ask you to pick a
name other than your own to call you by.  We will
give you a tag with that name on it.  You can expect
that some study staff will sit in and take notes
during your focus group session.  Also, we plan to
record the session on audio tape.  Only study staff
will be able to use the tapes.  The tapes are to help
learn more about what is said by all of you as you
discuss the topics.  At the end of the study, we will
erase the tapes and throw them away.”
4. Avoidance Requirements - On occasion, participation in a
CDC research project may mean suspending certain
functions required for study testing procedures, avoiding
certain drugs which could confound research results, or
discontinuing certain lifestyle practices.  Prospective
participants need to know about these requirements in
order to give their informed consent.  Suggested readable
wording akin to that which the IRB has approved to
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address this contingency in CDC consent forms include:
“During this study, we ask that you not take any
antimalarials other than what the team gives you.”
*****
“Rifampin may interfere with other drugs you may
be taking.  We will discuss your list of drugs, then 
tell you of possible problems with any of them.”
*****
“We ask people in the study not to receive any other
vaccine.  This applies to the 2 weeks before and the
2 weeks after each meningococcal serogroup B
immunization.  If you need to receive any other
immunization during the study period, please tell a
member of the study staff listed above.”
*****
“Between the visit today and the one next week, we
ask that you not have sex.  If you feel that you
cannot do this, we ask that you use a condom when
you do have sex.”
*****
“You must not eat or drink anything (other than
water) from after dinner until the morning of the
test.  At that time, we will give you a sweet cola
drink.  One test will be done before you drink the
cola and the other one 2 hours after drinking the
cola.”
 *****
“If you join the study, we will ask that you not eat
anything for 4 hours before the test.  In the test, you
will drink a can of orange juice, and then breathe
down a straw into a tube.  This provides a baseline
breath sample.  You will then drink a test solution;
30 minutes later you will again breathe down a
straw into a tube.  This is the test sample.”
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5. Refusal of HIV Test Results - CDC studies involving
serologic testing for HIV antibody remain fairly common. 
However, the issue of whether participants should be able
to refuse to get their test results is fading into obscurity. 
This is true at least in developing countries where antiviral
therapies are making the knowledge of one’s HIV
antibody status a life preserving necessity.  However, in
some domestic research situations, and in developing
countries, this issue remains alive.  Policy of the
Department of Health and Human Services (HHS)
developed in 1988 remains in effect on this issue.  In
summary, it says that, in domestic research, individuals
whose HIV test results are associated with personal
identifiers MUST be informed of their results and
provided with the opportunity to receive appropriate
counseling; they may not be given the option not to know,
either at the time they consent to the test or thereafter,
unless an exception is granted.
An exception to the HHS policy may be considered for
studies in foreign sites.  However, allowing a right to
refuse must be consistent with host country cultural norms
and the resources, capabilities, and official health policy
there.  Also, the IRB must determine that the modification
of policy to allow refusal is significantly justified by the
risk/benefit evaluation of the research project itself.  Since
the default is to not allow a “right to refuse HIV tests”,
suggested readable wording akin to that which the IRB has
approved in CDC consent forms include:
“If you choose to be in this study, we will take your
blood and test it for HIV antibody at CDC.  We will
give you the results of that test.  We will also explain
the results.  We will counsel you about what you
might do next and services open to you.” 
 6. The Use of Placebo Controls - When you conduct a
placebo controlled trial, your consent form must explain
what this is, why it is used, and how it will work. 
Suggested readable wording akin to that which the IRB
has approved in CDC consent forms includes:
“In this study your child will be put in one of two
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groups as a matter of chance.  Children in one
group will get the drug we want to test.  The other
group will get pills which look the same, but they
will have no drug in them.  They are harmless and
are meant to hide who has the drug.  This is so our
study doctors will give each child the same exam
and not look harder at one group over the other. 
This will give the drug the fairest test and allow us
to tell if it works.”
*****
“We are doing this study to see if giving this drug
late in pregnancy will also lower the chance of a
mother passing the virus to her baby.  To do this, we
will give some women the drug and give other
women a placebo.  A placebo is like a “sugar pill”
which has no benefit or risk to your baby’s health.”
 7. Conditions for Breaking the Study Code - In blinded
randomized clinical trials, and occasionally in other types
of CDC studies, there is a real prospect of breaking the
code before the study ends.  Prospective participants need
to hear about this possibility so that they understand the
operating rules, and are not surprised if it occurs.  Sample
wording might pick up from the example cited just above
and add:
“...to tell if it works.  Before the study ends, our
exams may tell that many children are getting ill
while others are staying well.  In that case, we may
look at the code that tells us which children are in
each group.  If this tells us that the drug is working,
we will end the study early and give the drug to
every child.”
RISKS OR DISCOMFORTS
Naturally, risks or discomforts are going to vary in type and
degree from one study to another.  The charge is to neither
understate nor overstate risks so that a prospective participant
will be able to make an informed choice about entering the
study.  The challenge is to explain those risks in a way that
prospective participants can understand.  The more common
risk situations that find their way into CDC consent forms are
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addressed below.  These begin with a common situation
where the risk is minimal. 
1. Rare or Nominal Risks - Even when risks or discomforts
are rare or minimal, you should discuss them in your
consent.  Examples of readable wording akin to that which
the IRB has approved for CDC consent forms include:
“We expect the risks to you for being in this study to
be rare, but we cannot rule them out.  For instance,
it may be hard to talk to your sex partner(s) about
your infection.  But you should try to do this even if
you don’t want to be in this study.”
*****
“All the steps to be carried out by this study have
been approved from a child safety standpoint.  They
are widely used in America.  There is a slight sting
from the shot.  For some children, there may be a
small bruise at the site of the shot that will quickly
go away.”
2. Risks from taking blood - Serologic testing is one of the
most common components of CDC research protocols. 
Whether this is done by finger stick or taking blood from a
vein, the consent needs to explain the risks entailed. 
Readable wording akin to that which the IRB has
approved in CDC consent forms include:
“You may feel a slight sting or “pinch” in your arm
when the blood is drawn.  You may also get a small
bruise where the needle went in.  Some people faint,
but this is rare.”
*****
“Drawing the blood may hurt a little.  Bruising,
bleeding, and rarely, infection could occur where
the needle enters your vein.”
*****
“The main risk to you in being part of this study is




taking your blood.  There is a small chance you
could get germs in the spot where the blood was
taken and it could get infected.  If the area around
the spot gets red and sore, you would need to go to
the clinic.”
*****
“Your child will feel a slight sting (like a pin prick)
when we take blood from a vein.  The hurt will be
over quickly.  The stick we use is sterile, so it will
not harm your child.  Also, the amount of blood we
take will not harm your child at all.  Your child may
have a bruise from where the needle went in, but
this will go away soon.” 
3. Questionnaire/Interview Risks - Nearly all CDC research
involves the use of some type of questionnaire or
interview as part of their study design.  Depending upon
the subject of the study, the risk may range from negligible
to substantial embarrassment, discomforts, or
psychological trauma.  As stated earlier, the procedures
section should spell out the focus of these proposed
interactions and highlight the subject matter which may be
problematic for the prospective participant.  In this
section, the foreseeable risks associated with those
questionnaire/interview aspects should be detailed. 
Suggested readable wording akin to that which the IRB
has approved in CDC consent forms include:
“When we do the survey, none of the private
questions we will ask you are about touchy matters. 
So none of them should make you uneasy.  But as
we said, you can choose to not answer any of them
that you wish, for any reason.”
*****
“As we said, our survey will ask you questions about
how you live and what you do.  As part of that, we
will ask about the type of sex you have, if you’ve had
an STD, and drugs you may use.  Those questions
may trouble you to think about or answer them, or
embarrass you.  But as we said, you can choose not
30Consent for CDC Research—A Reference
Note: Each example above contains a reminder that the participant is free to
decline to answer any item.  While this repeats what is said in the
Procedures section, the importance of this message warrants the
redundancy.
to answer any of them that you wish-for any
reason.”
*****
“In asking about the child you just lost, we know
that this may be hard for you to relive.  You face a
risk that this may depress you, perhaps a great deal. 
If you are not ready to be in this study, you may
need to see a doctor after to help you cope.  But as 
   
On occasion, circumstances of the research may suggest
that the risks of answering a questionnaire/interview are
balanced by certain risks in declining to respond.   For
example,
“If you choose to answer our questions, the only
risk is perhaps feeling bad if you tell us about giving
the tainted vitamins to other children in the house. 
That was not supposed to happen, but it is OK to
talk about this.  In fact, it is only bad not to talk
about it because one or more children might miss
the chance to get a needed test.”
4. Drug Side Effects - Most therapeutic agents that study
participants may be asked to take will produce side effects
to some degree.  Prospective participants need to know
about these side effects and their dimensions in order to
make an informed decision about joining the study.  When
you know how often certain side effects occur, include this
information in your consent form.  Suggested readable
wording akin to that which the IRB has approved in CDC
consent forms include:
“Our review of response forms we got between 1992
and 1994 showed that about 12% of person getting






this toxoid had side effects where they got the shot. 
Most often this is only redness, but it may swell up
and limit your arm movement.  In about 10% of
cases, the reports showed that people had more
general reactions.  This added up to one or more of
the following:  pain and soreness; itching; feeling
tired; feeling queasy or throwing up; seeing double;
a prickling feeling on the face and body; or a rash. 
If you have any of these, report them to the study
person whose name is on this consent form.”
5. After-Effects from Study Procedures - Some CDC studies
involve procedures from which participants may expect to
experience after-effects.  These should be described so
that prospective participants can make an informed
decision about whether they want to incur those risks. 
Suggested readable wording akin to that which the IRB
has approved in CDC consent forms includes:
“The apheresis process may also cause you to feel
some effects on your health.  One bad effect for
donors is that they may have a slight drop in their
red cells (anemia) or in their platelet count.  This
will not be severe and returns to normal over time. 
The long term effect of the drop in lymphocytes is
not known.”
*****
“Risks of white cell donation are the same as the
risks of giving blood.  These include feeling queasy,
throwing up, having chills, feeling light in the head
or fainting.  It can also involve blood loss, seizures,
and infection and swelling or bleeding around the
needle site.  The risk of giving white blood cells also
includes getting a blood infection and having
muscle cramps.  It can also involve getting a
tingling around the lips due to a reaction between
ACD-A (anti-coagulant) and your body’s calcium. 
These risks are rare and occur less than 1% of the
times people donate.  Another risk from white cell
donation is getting an air embolus (a bubble of air
that travels through the blood).  The risk of getting
an air embolus is very rare.  It happens less than
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.0002% (less than 1 in 500,000) of the times people
donate.  An air embolus is a very rare but serious
risk, since it could result in stroke or death.”
6. Unforeseeable Risks - When indicated by prior safety
research, a statement should be added that a particular
treatment or procedure may involve risks which are
currently unforeseeable for the subject (or the embryo or
fetus, if a participant is or may become pregnant).
Suggested readable wording akin to that which the IRB
has approved in CDC consent forms includes:
“We do not expect any risks to you from being in this
study or our focus group.  While our focus group
leader is very good, it is an open discussion.  Issues
discussed could make you feel uneasy, and you could
reveal private things that you later regret.” 
*****
“This vaccine has been used in other countries, but it
has not been used in the U.S. until now.  This makes
its use here experimental.  We do not expect risks to
your child from taking this vaccine beyond those we
have already told you about.  But we cannot be
certain until we study the vaccine here.  We will stop
the study at once if we learn of any new risks.” 
BENEFITS
Similar to the Risks or Discomforts section, the Benefits
section should give a balanced explanation of benefits that
prospective participants can expect.  It should also address any
benefits to others or to society at large.  Citing the latter grows
in importance proportionate to any decrease in direct benefits
to a person’s participation.
1. Benefits to the Participant - Sometimes, CDC studies can
have direct benefits to those who participate.  Suggested
readable wording akin to that which the IRB has approved
in CDC consent forms include:
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“We expect that if this vaccine works, it will keep
your infant from getting the hepatitis infection.”
*****
“The benefits to you of being in the study are
learning if you have this parasite so that you can get
proper care and treatment.”
*****
“The benefits of being in this study include knowing
your present health status and also knowing your
risk of developing AIDS.”
2. No Direct Benefits - When there is no foreseeable benefit
to the participant, regardless of potential benefits to others,
clearly explain this fact.  Suggested readable wording akin
to that which the IRB has approved in CDC consent forms
includes:
“You will get no direct benefit from being a part of
this study.  But helping to carry out this research has
a chance to tell us a lot about the disease.  If so, that
could be of future benefit to you or to someone you
know.” 
CONFIDENTIALITY - Common Situations
The Confidentiality section must affirm both that study
records will be kept confidential (try substituting “private” as
an inexact but less complex term) and physically secure from
unauthorized access.  As study information increases in
sensitivity, the urgency to explain confidentiality and security
also increases.  Making records safer is how you can have a
study considered “minimal risk” even though the data, were it
ever to be released, could pose a real problem for participants. 
Legally Unprotected Research - The most common situation is
that CDC research projects are conducted without specific
legal protections.  For reference, the legal protection which
could apply are sections 301(d) (Certificate of Confidentiality)








and 308(d) (CDC Assurance of Confidentiality) of the Public
Health Service (PHS) Act.  Also, a few states have stringent
confidentiality laws which apply to research involving human
participants.  Except where these specific protections apply, it
is inaccurate to use the term “strictly confidential” or its
synonyms (e.g., “totally” or “entirely” confidential) in the
consent process.  That simply assures more protection than the
investigators are able to provide, as study records indeed
would be subject to disclosure if ordered by judicial or law
enforcement authorities.  Suggested readable wording akin to
that which the IRB has approved in CDC consent forms
related to unprotected research includes:
“What we talk about and your test results will be kept
private to the extent allowed by law.  To protect your
privacy, we will keep the records under a code
number rather than by name.  We will keep the
records in locked files and only study staff will be
allowed to look at them.  Your name or other facts
that might point to you will not appear when we
present this study or publish its results.”
 
CONFIDENTIALITY - Less Common Situations
On occasion, a CDC study will have its records subject to
review by regulatory authorities.  Or a CDC study may be
further protected under the PHS Act.  Whenever any of these
situations apply, the Confidentiality section needs to explain
that information with identifiers will be shared with other
agencies.
1. Records are Subject to Review - On occasion, a CDC
study will be subject to outside review.  The usual
example is when the study is conducted in association
with a blood banking facility, whose records the Food and
Drug Administration may review.  Suggested readable
wording akin to that which the IRB has approved in CDC
consent forms for this situation includes:
“Emory Clinic will keep a private record of each time
you donate.  Only staff who are allowed will have
access to your records, except as the law may
demand.  Also members of the Food and Drug
Administration may look over your records during
their required reviews.”
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2. Allowed Use of “Strictly” in Describing Confidentiality -
When a CDC study is covered locally under stringent state
confidentiality laws which protect against court-ordered
disclosure, or a federal Certificate of Confidentiality
issued by CDC, which is even stricter, the consent to use
the term “strictly” in describing confidentiality (“privacy”
for readability) is allowable.  Suggested readable wording
akin to that which the IRB has approved in CDC consent
forms related to such protected research includes: 
“Your records in this study are strictly private.  No
one other than study staff can ever look at them
unless you agree to it.  This is because the study has
been granted a Certificate of Confidentiality under a
federal law [Section 301(d) of the Public Health
Service Act].  This means that the records of this
study may not even be called into federal, state, or
local court without your OK.  That applies forever.”   
     
2. CDC Assurance of Confidentiality - Some CDC research
projects are granted an Assurance of Confidentiality under
Section 308(d) of the PHS Act.  An Assurance of
Confidentiality also offers stringent protection for study
records, denying disclosure from court order or other
access.  However, it is important to understand that an
Assurance only protects study records held at CDC and by
its contractors.  If the study is conducted through local
sites and study records are maintained there, those records
are not covered by the Assurance; they are subject to the
limits of any coverage afforded by state or local law.  The
consent form should try to explain how this works.  Below
is an example of how this can be done in a fairly straight-
forward fashion, bypassing details.  The alternative
passage which follows is a more comprehensive
explanation, variations of which are found in several CDC
consent forms.
[Short Version]
“Your test results at CDC are kept private by an
Assurance of Confidentiality under the Public
Health Service Act [Section 308(d)].  This means that
CDC may not let those out with information that
identifies you for any reason unless you agree.  The
records of what we discuss in the survey will be kept
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here in Tampa.  We will keep them private to the
extent allow by state law.”
[Long Version]
“CDC is that part of the U.S. Public Health Service
that collects the nation’s data on HIV and AIDS. 
The data that come to CDC are reports of persons
whose doctors diagnose them with AIDS or suspect
they have AIDS.  CDC uses the data to count
numbers of cases of HIV/AIDS, and to conduct
studies of who gets HIV/AIDS and how.  Nobody is
ever named.  State and local public health people use
the data to help learn about HIV/AIDS and control
its spread.
Any HIV/AIDS data that come to CDC through this
system that may identify a person in any way, will be
kept private.  This is assured under section 308(d) of
the Public Health Service Act (42 U.S.C. 242K and
242m(d)).  As a rule, CDC does not get reports which
include a person’s full name, address, or phone
number.  Instead, CDC gets data which are tagged
with a code.  This code is made from letters and
numbers based on a person’s last name.  In the rare
event that CDC does receive your name, CDC can
only release the data with your name if you give your
written consent for the purpose.  Sometimes, CDC
needs to confirm the data in reports or to alert
doctors or public health people of data in the reports. 
Each time, CDC will only disclose the minimum
amount of facts about you needed to get that done. 
Your name will not be given.  Data kept by state and
local public health people are held private as allowed
by state and local law.
The Director of CDC approves research projects
about HIV/AIDS only under strict conditions that
keep private any facts about people.  If a research
person outside of CDC needs HIV/AIDS facts which
could identify a person, that research person must
sign a certificate.  In this, he or she vows to keep all
data private and to disclose nothing about a person
without the person’s written consent.  This vow has
the force of U.S. law.




Who Pays for Various
Procedures
CDC is not allowed to disclose any HIV/AIDS data
that may identify a person without their written
consent to anyone for any non public-health reason. 
This means that CDC may not disclose these data to
the public, to parties in any lawsuit or court case, or
to private companies, such as insurance companies
or employers.”  
COST/PAYMENT  - Common Situations
Beyond what its title indicates, this section needs to cover
three important financial aspects of a research project.  These
are:
1. Who Pays for Various Procedures - This section needs to
clarify who covers the expense of various procedures, e.g.,
examinations, tests, vaccines, or therapies that the
prospective participant would receive by joining the study. 
In most cases, the study would cover these costs, and the
prospective participant needs to know that.  Suggested
readable wording akin to that which the IRB has approved
in CDC consent forms includes:
“The only cost to you for being in our study is
the time you must spend and what it costs you to
get here today.”
2. Payment to Participate - CDC studies commonly pay
persons for being part of the research (with money, gift
certificates, etc.).  It is acceptable in CDC consent forms
to describe payment as reimbursement for their time,
trouble or inconvenience, discomfort, and out-of-pocket
expenses for being in the study.  It is not acceptable to
describe payment so it may be read as the purchase of a
person’s participation in research, which may be viewed as
coercion.  However, the IRB recognizes that on occasion
the amount may be much higher than normal (e.g., $250 -
$350 for leukapheresis) to meet market prices or to
acknowledge the relative risk and/or discomfort of a
particular clinical procedure.  Ideally, that issue is
addressed in this section, but is also appropriate in the
Procedures section within the context of what is required
of a participant.  It should never appear in the Benefits
section, because that sends a wrong message.  Suggested
readable wording akin to that which the IRB has approved





in CDC consent forms include:
“We will give you $25 to repay you for the time you
must take and any costs to you for being in our study. 
We will give you this $25 if you complete the study,
or if you choose to drop out before it ends.”
*****
“After your focus group, we will give you $20.  This
is to help repay you for the time you spent with us
and the cost of coming to be in our study.  We will
give you this whether you finish the focus group or
decide to withdraw before it ends.”
COST/PAYMENT  - Less Common Situations - When any
of the following less common situations arise, they must be
adequately addressed in the consent form.
1. Who Pays when Research Merges with Care - On
occasion, a research project will be conducted as part of a
medical procedure for which the participant would
normally pay, or a research procedure (e.g., examination
or test) may indicate the need for further diagnostic work-
up or curative therapy.  Your consent form must explain
who pays for what pieces of this continuum.  Suggested
readable wording akin to that which the IRB has approved
in CDC consent forms includes:
“The test we do for this study will be done at no cost
to you.  But if the test shows that you may have this
health problem, you will need to pay for seeing your
doctor.  You should also plan to pay for a test to
confirm if you have it.  If so, you will also pay for the
cost of the drugs to treat it.”
2. Payment Tied to Completion - Typically, payment is not
tied to the completion of participation in the study in order
to avoid the appearance of a penalty for withdrawing from
the research.  However, a study’s success can depend
heavily on participants finishing the research process. 
These studies usually involve a narrowly defined cohort
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and multiple steps, such as serial blood testing, repeated
questionnaires, or before-and-after testing of some type
surrounding an expensive or critical intervention.  
To emphasize the importance of completing the study, you
may want to break payments into segments, with the value
increasing for each succeeding segment of research. 
Explain this system to prospective participants by
indicating that the higher payments recognize a larger time
commitment necessitated by participating in successive
phases in the study.  However, do not overtly characterize
any payment as a “bonus” for completion.  In order to
make the point about the importance of completing the
research process, the investigator must:
(a) be completely clear in the Procedures section of the
consent that each participant’s completion is critical to
the research and that individuals should reconsider
joining the study if they do not now believe they can
complete it.  For example,
“This study will not succeed unless we have
enough people who see it through from start to
finish.  Thus, we ask you to join the study only if
you think that you may be able to do that.”
(b) break up the payment into increments linked to steps
in the research process, so that the payment schedule
can be explained in the Costs/Compensation section
within the context of the need for completion.  For
example:
“We will give you $25 for today’s visit to pay for
your time and costs.  Since each visit after that
adds to the time you must give us, we will add $5
to that payment each time.  Thus, we will be
giving you $40 for the last visit when you
complete the study.  We have told you why we
need you to complete the study, but we know
people may drop out.  If you decide to drop out
of the study, we will only repay you for your time
up to the last visit you made.”
  
(c) make it clear in the Right to Withdraw section that the
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sacrifice of repayment for withdrawing early is quite
apart from any rights or benefits they have and will
continue to enjoy regardless of their decision.  For
example:
“While we hope that you will stay to the end, you
are free to drop out of this study at any time.  If
you do, you will not get any more payments such
as those you got when you were in the study. 
But you will still be able to get all the care that
you got before; you will still get the same service
that you came to expect from us apart from
being in the study.” 
3. No Share in Commercial Results of Research - On
occasion, CDC studies will contain a possibility that the
research could result in the development of patentable
products with commercial application and value.  The
most familiar example today is the immortalization of
unique cell lines as the result of some type of genetic
research.  The CDC Office of General Council recently
collaborated with the IRB to craft easy-to-read language to
be used whenever a study has the potential of producing a
marketable product with any commercial value.  That
wording is:
"Your sample may be used in our research to help
our researchers invent or find something new.  The
aim is to use the findings and inventions to develop
new products that may improve the public health.  At
times, such findings or inventions may have a value
if they are made and sold.  The government or its
research partners may get a patent on these.  They
may also license these.  You would not share in any
money or other things that the government or any
company might get for what someone may invent or
find using your study samples.  We have no reason to
believe your samples will be used to invent or find
something new, but we want you to know what will
happen in case it does."
COMPENSATION 
The only use of the term “compensation” in the federal
regulations refers to money made available to injured research





participants to compensate them for disability, etc. 
Investigator often will use this interchangeably with
reimbursement (or “Payment” as used in this reference
document) which is to cover a participant’s out-of-pocket
expenses for being in a study.  As to the issue of
compensation for injury, the federal regulations requires it be
addressed in the consent from when a study involves more
than minimal risk.
   
No Compensation Provision for Injury - When a study
involves more than minimal risk, CDC requires a notification
in the consent form about compensation for injury.  This
statement should indicate that CDC has made no provision to
pay for needed care or for restitution should a person be
injured through participation in the study.  This does not
preclude an injured participant from taking legal action to
seek redress.  It only makes it clear that prospective
participants should not expect CDC to step forward with
financial help or to pay their losses if something goes wrong. 
Suggested readable wording akin to that which the IRB has
approved in CDC consent forms include:
“Neither University Hospital nor CDC has set aside
funds to pay you if a mishap occurs.  If you are harmed
as a result of this project, we will give you emergency
health care.  You should not expect to receive other
payment, and we will bill you or your insurer in the
usual manner.”
*****
“Doctors at the Clinic will arrange care for any physical
harm that happens from being in the study.  But neither
Emory University nor CDC has funds set aside to pay
you for costs from being hurt.”
RIGHT TO REFUSE OR WITHDRAW - Common
Situations
Each person recruited for a CDC study has the right to refuse
to participate.  In addition, each participant in every CDC
study has the right to withdraw, at any time and for any
reason.  In either case, the decision should involve no loss or
sacrifice of services to which the person has a right to expect
to receive.
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WITHDRAW - Common
Situations
RIGHT TO REFUSE OR
WITHDRAW - Refusal/
Withdrawal Rights
Refusal/Withdrawal Rights - Note that this reference
document calls for citing the first of these assurances in the
Procedures section.  Given the importance of this message, it
is worth repeating here, in a separate section.  It is critical that
this section be written in a way that prospective participants
can understand easily.  For example,
“As we said before, you are free to join the study or
not.  If you do not join, you will not lose any health
care service that you expect to get apart from this
study.  If you decide to join the study, you are also
free to drop out later for any reason.  In that case
too, you will not lose any health care service that you
may expect apart from this study.”
*****
“You are free to join the study or to decide not to
join.  You may also leave the study at any time, for
any reason.  If you decide not to join, or to drop out
later, you will lose no health care that you may
expect apart from this study.” 
RIGHT TO REFUSE OR WITHDRAW  - Less Common
Situations
Some studies may involve important consequences of
withdrawal which may not be apparent to a prospective
participant.  These studies may involve a more complicated
process of withdrawal than simply not showing up.  When
there are consequences of withdrawing or when there is a need
and procedure for an orderly withdrawal, these aspects should
be addressed in the consent form.  In addition, when the study
may include an investigator’s decision that certain participants
may lose their eligibility to continue, prospective participants
need to know that staying in or dropping out is not necessarily
their choice alone.
1. Consequences of Withdrawal - A participant is free to
withdraw, at any time and for any reason.  However, in the
interest of informed consent, the investigator must explain
the consequences of a participant's decision to withdraw
from the study.  Sometimes the circumstances of the study
can present a serious challenge to balance the need for
candor with the need to avoid coercing study participants. 
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Withdrawal Consequences 




“As we said, you have the right to drop out.  But you
should know that the study may not reach its goal if
too many people drop out.  Those whom we asked to
join are a small number who have been exposed to
this chemical.”  
2. Orderly Withdrawal - The investigator also needs to
explain the procedures for an orderly withdrawal. 
Extending from the example language  above, suggested
readable wording akin to that which the IRB has approved
in CDC consent forms includes:
“Also, we need to know if you do not show up
because you are ill or because you dropped out.  So,
if you decide to drop out, please tell a member of the
study staff before you do.”
    
3. Withdrawal by Study Staff - The circumstances in some
CDC studies may involve a real possibility that a
participant's further involvement may be terminated by
study staff without regard to the participant's consent. 
When that possibility exists the consent form needs to
explain circumstances under which this may happen.  
Suggested readable wording akin to that which the IRB
has approved in CDC consent forms includes:
“We told you that you are free to drop out of the
study at any time and for any reason.  You also
should know that the study staff could end your part
in the study.  This may happen if you miss one visit
and your return is not within 3 days of that date. 
You will be dropped from the study if you miss two
visits in a row.  This is because the drugs you are
taking in this study need to be given on or near the
set visit dates.  If not, our study will not be able to use
the results of your blood tests.  Staying in the study
after that would be of no value to us or to you.”   
STORAGE OF SPECIMENS FOR FUTURE TESTING  -
Common Situations 
The Procedures section covered the storage of specimens for
future testing when the samples were to be made irrevocably
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anonymous.  The decision to store “identifiable specimens” -
this is, specimens stored in such a way that they could be
linked to the donor, involves several issues.  It is best to
address them in a separate section of the consent form.
 
1. Components of Storage Consent for Identifiable
Specimens When identifiable specimens are to be stored
in a CDC study, several possible components must be
weighed as part of the consent form for collecting them. 
How these components are addressed in the consent form
depends upon the clarity of the plans for future testing. 
The amount of information required in a consent form is
proportional to the obscurity of those future testing plans. 
These components, along with the various possibilities for
future testing, are presented below.  Along with them is
suggested wording akin to that which the IRB has
approved in CDC consents related to stored identifiable
specimens:
a. Explicit Plans for Future Testing - Future plans for
testing stored identifiable specimens are usually the
clearest whenever that testing directly relates to the
study through which they were collected.  In this case,
the investigator’s explanation is straightforward, and
indicates that test results of any health significance will
be returned.  For example:
“We plan to test your stored samples when we
have new methods for finding antibody to
measles.  If any test results seem to have meaning
for your health, we will inform you or your
doctor, as you direct.”
  
  Under these circumstances, you may want to explain
other future tests you anticipate.  For example:
“We plan to test your stored samples when we have
new methods for finding antibody to measles.  The
only other testing we might do on your sample is to
check your immune status to other childhood
diseases.  If any test results seem to have meaning for
your health, we will inform you or your doctor, as you
direct.”    
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Explicit Plans for Future
Testing
You may also wish to specify any sensitive types of
testing that will not be done in order to improve
acceptance.  For example:
“We plan to test your stored samples when we
have new methods for finding antibody to
measles.  The only other testing we might do on
your sample is to check your immune status to
other childhood diseases.  If any test results seem
to have meaning for your health, we will inform
you or your doctor.  We plan to do no genetic
testing on your sample.”    
b. Unclear Plans for Future Testing - Storage with CDC
studies, even of identifiable specimens, most often is
for unspecified future research purposes.  The value of
such specimens is enhanced by the ability to link them
with other clinical and epidemiologic data on the
donor.  However, the inability to be specific forces an
investigator to cover a range of contingencies, e.g..
“We ask you to agree to freeze part of your blood
and other fluid samples at CDC.  We will use
these samples for research in the future.  We are
not sure what studies might be done.  But if any
test results seem to have meaning for your health,
we will inform you or your doctor, as you direct. 
Some tests we do may be experimental and have
no clear meaning to your health.  In those cases,
we will not report any results to you or your
doctor.  We will not test your samples for HIV or
other STDs.  Also, we do not plan to do any
genetic testing on your samples.”
c. When Genetic Testing is Possible - CDC is expanding
its genetic testing capabilities to study potential links
with diseases.  Hence, it may be prudent to use these
tests with a sample of stored specimens and to
anticipate this need when they are collected with no
clearly bounded future purpose.  However, testing to
identify a genetic predisposition to disease is different
from most other forms of biomedical testing in its
possible benefits and in its potential risks.  Therefore,
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SPECIMEN STORAGE
When Genetic Testing is
Possible
any possibility of genetic testing on identifiable stored
specimens needs to be preceded by a specific consent
to do this testing or a reconsent that would fully
explain the implications, e.g.,
“At some time we might ask to test your child’s
stored sample for a health problem that may
affect him in the future or which may run in your
family.  If so, we will tell you what that could
mean and we would only test if you agree to it.”
*****
“We may want to test your stored tissue sample to
look at your genes.  We would do this to see if you
are more likely than many other people to get a
disease.  If that happens, we will come to you first
to explain that testing and what it could mean. 
We will go ahead only if you agree.”
    
d. The Right to Exclude Certain Testing - When the
storage of identifiable specimens is for uncertain future
research purposes, prospective participants should be
given the right to identify any testing which they want
excluded from research.  But because a prospective
participant is unlikely to know the range of possible
research testing which CDC may do, it is appropriate to
cite some of the more sensitive types.  For example:
“You may exclude your stored sample from
certain types of tests that could be done during
future research.  Examples include genetic testing
to see if a disease may run in your family.  It
could also include testing for HIV (the virus
causing AIDS) or for other STDs.  Please note in
the space we provide any types of tests CDC
should not do on your stored sample.”
e. The Right to Refuse/Withdraw - The right to refuse to
enroll in research, or to withdraw from a project once
enrolled-both without penalty-are required components
of informed consent.  Future research involving stored
identifiable specimens nearly always is a project
separate from the study in which the specimens are
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The Right to Refuse/
Withdraw
collected.  When that is the case, the consent form
needs to state those withdrawal rights.  In addition, the
procedure for withdrawal from specimen storage will
be quite different from withdrawal from the source
study.  Therefore, the statement of this particular right
needs to include directions as to how to go about
withdrawing from storage.  For example:
“You may choose not to have your sample stored
for future research and still be part of this study. 
Also, you may agree to have your sample stored
and later decide that you want to withdraw it from
storage.  If so, you should call the study person
listed in this consent form and tell her to discard
your sample.  The sample will be discarded as you
instruct.  But any data from testing your sample
until that point will remain part of the research.”  
ALTERNATIVES (if appropriate)
The required elements of informed consent include the
disclosure of appropriate alternative procedures or courses of
treatment, if any, that might benefit the prospective
participant.
1. Specifying Alternatives - Many CDC protocols involve
providing diagnostic procedures, therapies, or vaccines. 
For protocols where this does not apply, there is no need
to include a section on alternatives.  However, when this
does apply, an investigator must inform the prospective
participant of what is available.  Examples of readable
wording akin to that which the IRB has approved in CDC
consents regarding alternatives include:
“If you do not want to be in the study, you will receive
the standard TB treatment given by the Botswana
National TB Program.”
*****
“If you do not wish to join this program, we will give
you care using the regular methods we have already
explained.”
*****




“You may choose not to be in his study.  If so, your
child’s care will not be affected in any way, now or in
the future.  You can get MMR vaccine from your
doctor or local health department.”
*****
“If you do not wish to join this amended part of the
TLC Study, you can get a blood-lead test through
your doctor for any of your children who got the
tainted vitamins.”
PERSONS TO CONTACT
This section discusses two elements that are common to
nearly every consent form.
1. Study contact - List the name of the study person to
contact with questions about participation, or concerning
injury sustained as the result of participation.  Also,
include instructions about how to make that contact.  This
section is likely to contain several $3 syllable proper
nouns; thus, it is important to try to minimize those where
the options exists to do so.  Suggested readable wording
akin to that which the IRB has approved in CDC consent
forms includes:
“If you have any questions about how the study
works, contact..., the chief study person, at ...” 
2. Contact for Participant Rights - The consent should also
provide the name of someone to contact with questions
about the person’s rights as a research participant.  This
should be someone who is not part of the study, i.e.,
responsible for the ethical conduct of research, such as a
local IRB chairperson, the CDC Deputy Associate
Director for Science, or the CIO Human Subjects Contact. 
This can be noted by continuing the sample wording
above with the following:
“If you have any concerns about your rights in the
study, contact ..., head of the University Human
Investigations Committee, at ...”
3. Contact in case of injury - The consent should also provide
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Contact in Case of Injury
the name of someone to contact in case the participant
sustains an injury as a result of the research.  This can be
either the contact to answer study question (e.g., the
Principal Investigator), the contact for questions about the
person’s rights as a study participant, or someone else all
together.  Usually that is the Principal Investigator.  The
following is sample wording to cover that:
“If you think that you have been injured by being
in this study, contact..., the chief study person,
at...”
YOUR CONSENT 
In this section of the consent form, prospective participants
are asked to declare whether they will enroll in the study. 
This statement can be written in two different ways.
1. An “I” Construct Statement - The most common approach
is to write an “I” construct declarative statement, which
basically puts words in the mouth of the prospective
participants about everything that is understood.  It also
says that an opportunity has been given to have all
questions answered to the individual's satisfaction.  Use
care if you use this construct because its tone can be very
formal and it can invite the use of complex sentence
structures and polysyllabic words.  The examples below
illustrate how to use the “I” construct and easy-to-
understand language akin to what the CDC has approved
in consent forms:
“I agree to be in this study.  I have been given a
chance to ask questions and I feel that all of my
questions have been answered.  I know that being in
this study is my choice.  I know that after choosing to
be in this study, I may leave it at any time.  I know
that if I wish to leave the study at any time, I may
contact ...at...”
*****
“I have read this consent form.  I have had my
questions answered so that all parts of the study are
clear to me now.  I have received a copy of this
consent form.  I agree to my child being a part of this
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YOUR CONSENT
An “I” Construct Statement
YOUR CONSENT
A Construct Addressing the
Prospective Participant 
study.”
2. A Construct Addressing the Prospective Participant - We
recommend addressing the prospective participant rather
than using the “I” construct.  This format may to be easier
to understand and has a more informal tone.  This is the
only practical format to use in preparing an oral consent
script.  An example of easy-to-read wording akin to that
which the IRB has approved in CDC consent form
includes:
“We have given you a copy of the consent form. 
When you sign below, it shows that you agree to let
your child be part of the study.  If there is any part of
this form which is unclear to you, be sure to ask
questions about it.  Do not sign until you get solid
answers to all of your questions.  When you are ready
to let your child be part of the study, sign your name
on the line below.” 
SIGNATURE LINES, APPROVAL BOXES, WITNESS
SIGNATURE LINES, DESIGNATIONS, AND REFUSAL
The end of the consent form involves some conventions which
an investigator needs to observe.  These include the
positioning of signature lines, using “check-off” boxes to
signify special approvals, allowing for designations,
explaining what witnesses are witnessing, and the issue of
indicating refusal to participate.
1. Signature Line Position - The signature line for the
prospective participant to enroll in the study should be
positioned after any special “check-off” boxes, such as for
storage.  This is to reinforce the concept that a prospective
participant can disagree to future testing and still take part
in the present study.
2. Approval Boxes - Many CDC studies involve procedures,
such as specimen storage or identifying who should get
test results, which call for separate specific consents. 
Using separate signature lines can be confusing.  The
clearest, most efficient way to obtain such special consents
is to provide “check-off” boxes.  For example:
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“Please Check One Box
 I give consent for my blood to be stored at CDC
under the conditions outlined in this consent
form.
 I DO NOT give consent for my blood to be
stored at CDC for future research.”
3. Witness Signature Line - CDC consent forms sometimes
include a witness signature line.  If a witness is required,
craft language for that signature line to describe what the
person will witness.  This can be from just witnessing the
prospective participant’s signature to observing the entire
consent process, including the signature.  The statement
accompanying the witness signature line should reflect
the witness’ role; it should also be realistic.  For example,
it should not say “I confirm that the prospective
participant completely understood the consent form and
got satisfactory answers to all of his/her questions.” 
More realistic wording might be:
“I observed the process of consent.  The prospective
participant read this form, was given the chance to
ask questions, appeared to accept the answers, and
signed to enroll in the study.” 
 
4. Designations - When a protocol involves current or future
testing with participant identifiers, the participant should
be given the right to designate the routing of the results of
those clinical tests.  There are exceptions where the tests
are experimental, in which case results will not be
returned.  However, prospective participants are
explicitly informed of this in the consent.  Also, there
may be tests about which the investigators justly feel
uncomfortable having results going to the participant
rather than a physician who can interpret them and
explain their implications.  The consent form should be
explicit about this as well when it applies.  Otherwise, the
consent form should give the prospective participant the
option to designate if results should be sent to them or to
their doctor.  Space should be devoted to designating the
physician’s name and address in the event that option is
selected, e.g.,
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“Please give any facts about my health (   ) directly to
me or (    ) directly to my doctor (address below).” 
    





2 Developed by Harold C. McGraw, Office of Educational Research, Baltimore County
Schools, Towson, MD.
3 Doak, Cecilia C., Leonard G. Doak, and Jane H. Root (1995). Teaching Patients with Low
Literacy Skills.  New York: J.B. Lippincott Co. 36-59.
4 Ibid: page 59 cites a 1979-81 test of the method conducted by Patient Learning Associates,
Inc., of Potomac, Maryland, in which the SMOG formula performed exceptionally when
used to grade materials presented to 291 individuals graded by accepted methods as having




The SMOG2 formula is a recommended3 and tested4 method for grading the readability of written
materials.  The method is quick, simple to use and particularly useful for shorter materials, e.g., a
study’s information pamphlet or consent form.  To calculate the SMOG reading level, begin with
the entire written work being assessed and follow these steps:
1. Count off 10 consecutive sentences near the beginning, in the middle, and near the end of the
text.  If the text has fewer than 30 sentences, use as many as are provided.
2. Count the number of words containing 3 or more syllables (polysyllabic), including repetitions
of the same word.
3. Look up the approximate grade level on the SMOG conversion table below:
Total P olysyllab ic Approximate Grade Level
       Word Count             (±1.5 Grade s)
          1-6   5
     7-12   6
   13-20   7
   21-30   8
   31-42   9
   43-56 10
   57-72 11







When using the SMOG formula:
o A sentence is defined as a string of words punctuated with a period, an exclamation mark, or
a question mark.  Consider long sentences with a semi-colon as two sentences.
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o Hyphenated words are considered as one word.
o Numbers which are written should be counted.  If written in numeric form, they should be
pronounced to determine if they are polysyllabic.
o Proper nouns, if polysyllabic, should be counted.
o Abbreviations should be read as though unabbreviated to determine if they are polysyllabic. 
However, abbreviations should be avoided unless commonly known.
o If the written piece being graded is shorter than 30 sentences, approach it as follows:
-- Count all of the polysyllabic words in the test.
-- Count the number of sentences.
-- Find the average number of polysyllabic words per sentence, i.e.:
   Total # of polysyllabic words   
                Average =     Total # of sentences
-- Multiply that average by the average number of sentences short of 30.
-- Add that figure on to the total number of polysyllabic words.
-- Compare the number of polysyllabic words in the SMOG conversion table.
SPANISH READABILITY FORMULAS
Crawford, A.N. (March 1984).  A Spanish language Fry type readability procedure: Elementary level. 
Los Angeles: Bilingual Education Paper Series, Evaluation Dissemination and Assessment Center,
California State University, Los Angeles, 7:1-17.
Garcia, W.F. (1976).  Assessing readability for Spanish as a second language: The Fry graph and cloze
procedure.  Unpublished doctoral dissertation, Teachers College, Columbia University.
Gilliam, B., Pena, S.C., and Mountain, L. (1980).  “The Fry graph applied to Spanish readability.”  The
Reading Teacher, 33:426-430.
Spaulding, S. (1956).  “A Spanish Readability formula.”  The Modern Language Journal. 40:433-441.
Spaulding, S. (1951).  “Two formulas for estimating the reading difficulty of Spanish.” Educational
Research Bulletin, 30:117-124
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The Fry Readability Scale
Directions:
! Select three 100-word passages from the beginning, end, and approximate middle of
the consent form.
! Count proper nouns, numerals, and initializations as words.
! Count the number of syllables, counting each symbol in numerals and initializations as
one syllable, e.g., 1997 as 1 word and 4 syllables; CDC as 1 word and 3 syllables.  A
suggested easy way to count is to put a mark above every syllable beyond 1 in each
word, count the number of marks, and add 100.
! Count the number of sentences in each 100 words, estimating the length of the fraction
of the last sentence to the nearest 1/10th.
! Add the number of sentences and the number of syllables and divide each total by 3.
! On the Fry Graph below, find the average number of sentences on the side scale and
find the average number of sentences on the top scale.  Where the points meet indicates




Easy-to-Read Replacement Words/Phrases for Polysyllabic Terms Common to CDC Consent Forms
Common Polysyllabic Possible Replacement
Terms in CDC Consents Words/Phrases
Additional information about Other facts about/more facts about
Allowing Letting
Another Any other/More/One more
Blood will be collected We will take blood 
By agreeing If you agree
By telephone By phone





Continue/Continued Go on/Keep on going/Kept on going
Contracting Getting
Convenient Handy
Currently receiving Now getting
Decision Choice
Deleted Erased
Description A statement which describes
Determine whether Learn if
Developed Put in place




Educational background Level of schooling
Enrolling Joining/being in
Entitled to otherwise Have a right to receive apart from this
Especially Mainly
Evidence of Signs of/proof of
Explanation A statement which explains
Exposure to Risk of getting/being exposed to
For example For instance
For study purposes To carry out the study
General/generalized Wide spread
However But/yet
Implemented Put in place
In addition Also
Including Along with




Interested in... Would like to know about...
In this community Around here
Make it possible to.. Allow us to...
Medical record Health record
60
Easy-to-Read Replacement Words/Phrases for Polysyllabic Terms Common to CDC Consent Forms
(Continued)
Common Polysyllabic Possible Replacement
Terms in CDC Consents Words/Phrases
Monitor Check on
Nausea Upset stomach/feeling queasy
Negligible Small
Participate/participating Be in/being in




Pregnancy, during When you are pregnant
Pregnancy outcomes Birth outcomes
Previous studies Studies done before
Previously unrecognized virus/ Virus we did not know about 
   recently discovered...      before now
Protected Kept private






Relevant Tied in with
Requested Asked for
Researchers/Scientists People doing the study
Resulted Came from
Satisfactory OK/fine
Schedule an appointment Set a time
Several Some/a few/a number of
Specimens Samples
Sexual behaviors Types of sex
Sexually transmitted diseases VD or (STDs)
Study coordinator The person who leads the
     study
Substantial Large/big
Suggested Pointed to
Thank you for volunteering to be in... Thank you, we are glad that 
          you agreed to be in...
The information we collect What you tell us
To the extent legally permissible To the extent allowed by law
Transmitted Passed on to other people
Understand Learn/see
Vomiting Throwing up
Your understanding of ... What you know about...
